Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension

J Heart Lung Transplant. 2010 Jul;29(7):817-8. doi: 10.1016/j.healun.2010.02.004. Epub 2010 Apr 2.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Administration, Oral
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure / drug effects
  • Bosentan
  • Contraindications
  • Heart Failure
  • Heart Transplantation*
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Piperazines / administration & dosage
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use*
  • Prospective Studies
  • Purines / administration & dosage
  • Purines / pharmacology
  • Purines / therapeutic use
  • Retrospective Studies
  • Sildenafil Citrate
  • Sulfonamides / administration & dosage
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use*
  • Sulfones / administration & dosage
  • Sulfones / pharmacology*
  • Sulfones / therapeutic use*
  • Vascular Resistance / drug effects*
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Bosentan